Biomarker ID | 353 |
PMID | 18559597 |
Year | 2008 |
Biomarker | Vascular endothelial growth factor (VEGF) |
Biomarker Basis | Concentration Based (pg/ml) |
Biomolecule | Protein |
Source | Plasma |
Subjects | Humans |
Regulation | Increased with Biochemical Recurrence |
Odds Ratio/Hazard Ratio/Relative Risk | Univariate: (Rate Ratio: 1.47); Multivariate: (Rate Ratio: 1.71) |
Effect on Pathways | Pathways Include:-S1P/S1P3 pathway, VEGFR1 pathway,Heart development,Actions of nitric oxide in the heart,Fibroblast growth factor 1 |
Experiment | Biochemical Recurrence Vs no Recurrence in 5 years |
Type of Biomarker | Prognostic |
Cohort | 423 patients treated with radical prostatectomy and bilateral lymphadenectomy for clinically localized prostatic adenocarcinoma were chosen. |
Senstivity | NA |
Specificity | NA |
AUC | Univariate: Concordance Index: 58.1; Multivariate: Concordance Index: 71.2 |
Accuracy | NA |
Level Of Significance | Univariate: p= 0.002; Multivariate: p=0.008 |
Method Used | enzyme immunoassays |
Clinical | No |
Remarks | Univariate Analysis. Biochemical recurrence was defined as a sustained elevation, on two or more occasions, of serum total prostate-specific antigen >0.2 ng/mL |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | VEGFA |